The Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) drugs in development market research report provides comprehensive information on the therapeutics under development for Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease). Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) and features dormant and discontinued products.

GlobalData tracks 40 drugs in development for Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) by 38 companies/universities/institutes. The top development phase for Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) is phase i with 16 drugs in that stage. The Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) pipeline has 40 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) pipeline products market are: Boehringer Ingelheim International, Avalyn Pharma and Foresee Pharmaceuticals.

The key targets in the Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) pipeline products market include Prostacyclin Receptor (Prostaglandin I2 Receptor or Prostanoid IP Receptor or PTGIR), Macrophage Metalloelastase (Matrix Metalloproteinase 12 or Macrophage Elastase or MMP12 or EC 3.4.24.65), and Lysophospholipase (Phospholipase B or EC 3.1.1.5).

The key mechanisms of action in the Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) pipeline product include Prostacyclin Receptor (Prostaglandin I2 Receptor or Prostanoid IP Receptor or PTGIR) Agonist with three drugs in Phase III. The Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) pipeline products include eight routes of administration with the top ROA being Oral and six key molecule types in the Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) pipeline products market including Small Molecule, and Monoclonal Antibody.

Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) overview

Interstitial lung disease (ILD) is a term that covers a variety of disorders that cause scarring or inflammation of the lung tissue. The scarring or inflammation affects the ability of the lungs to transfer oxygen to the blood. ILD can be caused by many factors, such as exposure to environmental toxins, certain medications, autoimmune diseases, infections, or unknown causes. Some common types of ILD are sarcoidosis, idiopathic pulmonary fibrosis, hypersensitivity pneumonitis, and eosinophilic pneumonia. ILD can cause symptoms such as shortness of breath, dry cough, fatigue, and chest pain. The diagnosis of ILD is based on medical history, physical examination, chest imaging, lung function tests, and sometimes lung biopsy. The treatment of ILD depends on the specific type and cause of the disease, but may include corticosteroids, immunosuppressants, antifibrotics, oxygen therapy, pulmonary rehabilitation, or lung transplantation. ILD is a chronic and progressive condition that can affect the quality of life and survival of patients.

For a complete picture of Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease)’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.